Videos on psilocybin therapy and depression treatment

Psychedelics, Clinical Trials and the Profit Motive

Dr James Rucker

Most new treatments in medicine are tested for safety and effectiveness through a series of legally-mandated clinical trials. New treatments cost around $300,000,000 to develop, often over a decade or more. Historically, governments have chosen to delegate that cost to the profit-driven pharmaceutical industry.

This creates an uneasy tension with healthcare. Elements of this tension appeared in the psychedelic field when UK-based Compass Pathways announced a switch to a for-profit model. Compass fund KCL, where I lead the Psychedelic Trials Group, to undertake trials with psilocybin.

I will discuss our work to date, attempt to dispel some myths and conclude by suggesting that, whilst the profit motive is by no means an ideal fit, it is likely to be a necessary part of challenging stigma and bringing a paradigm-shifting therapy to those who would never otherwise have access to it.

Psychedelics in Psychiatry

Dr James Rucker

At the Swedish Global Psychedelic Dinner, organized in collaboration with Multidisciplinary Association for Psychedelic Studies, we had the fortune of listening to Dr James JH Rucker describing recent clinical trials with psilocybin for depression.

James Rucker, MBBS MRCPsych PhD, is a psychiatrist working in the NHS in South London who also is a Clinical Lecturer at Kings College London. He specialises in mood disorders, psychopharmacology, genetics and psychedelic assisted psychotherapy.

The use of psychedelics in Psychiatry

Dr James Rucker

As our understanding of the causes of mental illness has developed, a growing number of pharmacological and non-pharmacological interventions have shown potential as novel treatments. While some of these remain experimental, others are emerging into routine clinical practice in the UK and around the world.

Drawing on recent exciting research findings, many of these interventions shine a new light on the causes and pathologies associated with psychiatric illnesses and are paving the way towards the future of psychiatry. From psychedelics to gut microbiome, Dr James Rucker explains the history and science behind using psilocybin, ketamine, MDMA, cannabis, transcranial magnetic stimulation, triple chronotherapy, and gut microbiome to treat psychiatric disorders.

Medical Psychedelics Working Group

Dr James Rucker

On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group. Building off the success of the Medical Cannabis Working Group, the Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners. Drug Science provides an evidence base free from political or commercial influence, creating the foundation for sensible and effective drug laws, by delivering, reviewing and investigating scientific evidence relating to psychoactive drugs.

Psychedelic Treatments

Dr James Rucker

Dr. James Rucker of King’s College London shares the results of a pilot study using psilocybin to treat depression.